INTERVENTION 1:	Intervention	0
1250 mg/m^2 Capecitabine + Docetaxel	Intervention	1
capecitabine	CHEBI:31348	12-24
1250 mg/m^2 capecitabine (Xeloda®) orally twice a day on days 1 to 14 of each 3 week cycle, in combination with docetaxel (Taxotere®) 75 mg/m^2 intravenous on day 1 of each 3 week cycle.	Intervention	2
capecitabine	CHEBI:31348	12-24
day	UO:0000033	50-53
day	UO:0000033	57-60
day	UO:0000033	159-162
week	UO:0000034	80-84
week	UO:0000034	175-179
INTERVENTION 2:	Intervention	3
825 mg/m^2 Capecitabine + Docetaxel	Intervention	4
capecitabine	CHEBI:31348	11-23
825 mg/m^2 capecitabine orally twice a day on days 1 to 14 of each 3 week cycle, in combination with docetaxel 75 mg/m^2 intravenous on day 1 of each 3 week cycle.	Intervention	5
capecitabine	CHEBI:31348	11-23
day	UO:0000033	39-42
day	UO:0000033	46-49
day	UO:0000033	136-139
week	UO:0000034	69-73
week	UO:0000034	152-156
Inclusion Criteria:	Eligibility	0
women >=18 years of age;	Eligibility	1
age	PATO:0000011	20-23
>=1 target lesion;	Eligibility	2
target	BAO:0003064	4-10
locally advanced or metastatic breast cancer;	Eligibility	3
breast cancer	DOID:1612	31-44
demonstrated resistance to anthracycline;	Eligibility	4
anthracycline	CHEBI:48120	27-40
>=2 regimens of chemotherapy for advanced/metastatic disease.	Eligibility	5
disease	DOID:4,OGMS:0000031	53-60
Exclusion Criteria:	Eligibility	6
previous treatment with Xeloda, continuous 5-fluorouracil infusion, or other oral fluoropyrimidines;	Eligibility	7
5-fluorouracil	CHEBI:46345	43-57
previous treatment with paclitaxel or docetaxel for advanced/metastatic disease.	Eligibility	8
paclitaxel	CHEBI:45863	24-34
disease	DOID:4,OGMS:0000031	72-79
Outcome Measurement:	Results	0
Time to Progression of Disease or Death	Results	1
time	PATO:0000165	0-4
disease	DOID:4,OGMS:0000031	23-30
death	OAE:0000632	34-39
Progression Free Survival was defined as the time from the date of randomization to the day of documented disease progression or death due to any cause.	Results	2
time	PATO:0000165	45-49
day	UO:0000033	88-91
disease	DOID:4,OGMS:0000031	106-113
death	OAE:0000632	129-134
Time frame: Event driven (after 350 events). Median observation time was approximately 16 months.	Results	3
time	PATO:0000165	0-4
time	PATO:0000165	64-68
median	BAO:0002174	45-51
Results 1:	Results	4
Arm/Group Title: 1250 mg/m^2 Capecitabine + Docetaxel	Results	5
capecitabine	CHEBI:31348	29-41
Arm/Group Description: 1250 mg/m^2 capecitabine (Xeloda  ) orally twice a day on days 1 to 14 of each 3 week cycle, in combination with docetaxel (Taxotere  ) 75 mg/m^2 intravenous on day 1 of each 3 week cycle.	Results	6
capecitabine	CHEBI:31348	35-47
day	UO:0000033	74-77
day	UO:0000033	81-84
day	UO:0000033	184-187
week	UO:0000034	104-108
week	UO:0000034	200-204
taxotere	CHEBI:46058	147-155
Overall Number of Participants Analyzed: 230	Results	7
Median (95% Confidence Interval)	Results	8
median	BAO:0002174	0-6
Unit of Measure: Months  7.9        (6.9 to 8.5)	Results	9
Results 2:	Results	10
Arm/Group Title: 825 mg/m^2 Capecitabine + Docetaxel	Results	11
capecitabine	CHEBI:31348	28-40
Arm/Group Description: 825 mg/m^2 capecitabine orally twice a day on days 1 to 14 of each 3 week cycle, in combination with docetaxel 75 mg/m^2 intravenous on day 1 of each 3 week cycle.	Results	12
capecitabine	CHEBI:31348	34-46
day	UO:0000033	62-65
day	UO:0000033	69-72
day	UO:0000033	159-162
week	UO:0000034	92-96
week	UO:0000034	175-179
Overall Number of Participants Analyzed: 229	Results	13
Median (95% Confidence Interval)	Results	14
median	BAO:0002174	0-6
Unit of Measure: Months  5.8        (4.9 to 7.1)	Results	15
Adverse Events 1:	Adverse Events	0
Total: 41/217 (18.89%)	Adverse Events	1
Febrile neutropenia 13/217 (5.99%)	Adverse Events	2
neutropenia	HP:0001875,DOID:1227	8-19
Neutropenia 6/217 (2.76%)	Adverse Events	3
neutropenia	HP:0001875,DOID:1227	0-11
Leukopenia 2/217 (0.92%)	Adverse Events	4
leukopenia	HP:0001882,DOID:615	0-10
Anaemia 0/217 (0.00%)	Adverse Events	5
Atrial flutter 0/217 (0.00%)	Adverse Events	6
atrial flutter	HP:0004749	0-14
Cardiac failure 0/217 (0.00%)	Adverse Events	7
Cardiogenic shock 1/217 (0.46%)	Adverse Events	8
cardiogenic shock	HP:0030149	0-17
Cardiopulmonary failure 0/217 (0.00%)	Adverse Events	9
Stomatitis all 5/217 (2.30%)	Adverse Events	10
stomatitis	HP:0010280,DOID:9637	0-10
Diarrhoea 2/217 (0.92%)	Adverse Events	11
Vomiting 2/217 (0.92%)	Adverse Events	12
vomiting	HP:0002013	0-8
Adverse Events 2:	Adverse Events	13
Total: 53/248 (21.37%)	Adverse Events	14
Febrile neutropenia 14/248 (5.65%)	Adverse Events	15
neutropenia	HP:0001875,DOID:1227	8-19
Neutropenia 4/248 (1.61%)	Adverse Events	16
neutropenia	HP:0001875,DOID:1227	0-11
Leukopenia 0/248 (0.00%)	Adverse Events	17
leukopenia	HP:0001882,DOID:615	0-10
Anaemia 1/248 (0.40%)	Adverse Events	18
Atrial flutter 1/248 (0.40%)	Adverse Events	19
atrial flutter	HP:0004749	0-14
Cardiac failure 1/248 (0.40%)	Adverse Events	20
Cardiogenic shock 0/248 (0.00%)	Adverse Events	21
cardiogenic shock	HP:0030149	0-17
Cardiopulmonary failure 1/248 (0.40%)	Adverse Events	22
Stomatitis all 0/248 (0.00%)	Adverse Events	23
stomatitis	HP:0010280,DOID:9637	0-10
Diarrhoea 2/248 (0.81%)	Adverse Events	24
Vomiting 2/248 (0.81%)	Adverse Events	25
vomiting	HP:0002013	0-8
